These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 29343622)

  • 1. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.
    Lan Y; Zhang D; Xu C; Hance KW; Marelli B; Qi J; Yu H; Qin G; Sircar A; Hernández VM; Jenkins MH; Fontana RE; Deshpande A; Locke G; Sabzevari H; Radvanyi L; Lo KM
    Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.
    Knudson KM; Hicks KC; Luo X; Chen JQ; Schlom J; Gameiro SR
    Oncoimmunology; 2018; 7(5):e1426519. PubMed ID: 29721396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).
    Jochems C; Tritsch SR; Pellom ST; Su Z; Soon-Shiong P; Wong HC; Gulley JL; Schlom J
    Oncotarget; 2017 Sep; 8(43):75217-75231. PubMed ID: 29088859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
    Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
    Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma.
    Khalili-Tanha G; Fiuji H; Gharib M; Moghbeli M; Khalili-Tanha N; Rahmani F; Shakour N; Maftooh M; Hassanian SM; Asgharzadeh F; Shahidsales S; Anvari K; Mozafari MR; Ferns GA; Batra J; Giovannetti E; Khazaei M; Avan A
    Life Sci; 2023 Sep; 328():121865. PubMed ID: 37336360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.
    Li T; Wang X; Niu M; Wang M; Zhou J; Wu K; Yi M
    Front Immunol; 2023; 14():1196970. PubMed ID: 37520520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
    David JM; Dominguez C; McCampbell KK; Gulley JL; Schlom J; Palena C
    Oncoimmunology; 2017; 6(10):e1349589. PubMed ID: 29123964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.
    Cheng B; Ding K; Chen P; Ji J; Luo T; Guo X; Qiu W; Ma C; Meng X; Wang J; Yu J; Liu Y
    Cancer Commun (Lond); 2022 Jan; 42(1):17-36. PubMed ID: 34981670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
    Strauss J; Heery CR; Schlom J; Madan RA; Cao L; Kang Z; Lamping E; Marté JL; Donahue RN; Grenga I; Cordes L; Christensen O; Mahnke L; Helwig C; Gulley JL
    Clin Cancer Res; 2018 Mar; 24(6):1287-1295. PubMed ID: 29298798
    [No Abstract]   [Full Text] [Related]  

  • 14. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
    Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
    Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
    Niu M; Yi M; Wu Y; Lyu L; He Q; Yang R; Zeng L; Shi J; Zhang J; Zhou P; Zhang T; Mei Q; Chu Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):94. PubMed ID: 37573354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
    Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity.
    Shi W; Lv L; Liu N; Wang H; Wang Y; Zhu W; Liu Z; Zhu J; Lu H
    Mol Ther; 2023 Jan; 31(1):66-77. PubMed ID: 36045584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation.
    Yu X; Li T; Shen Z; Jing H; Xie X; Zhou X; Shen Y; Yang Y
    Int Immunopharmacol; 2023 Mar; 116():109704. PubMed ID: 36689847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.